Literature DB >> 16741933

Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls.

A Szöke1, F Schürhoff, A Méary, F Mathieu, F Chevalier, A Trandafir, C Alter, I Roy, F Bellivier, M Leboyer.   

Abstract

Abnormal dopaminergic function in the prefrontal cortex (PFC) may be a key factor in the etiopathogeny of schizophrenia and bipolar disorder. Both schizophrenic and bipolar subjects have executive functions (EF) deficits, thought to reflect abnormal PFC function. The main inactivation pathways for dopamine in the PFC are enzymatic cleavage by the Carboxy-O-Methyl-Transferase (COMT) and reuptake by the nor-epinephrine transporter (NET). Our aim in this study was to replicate previous studies that investigated influence of the COMT genotype on EF in schizophrenic subjects, their relatives and controls and extend their scope by including bipolar patients, and their relatives and by exploring NET gene polymorphisms influence on executive performances. We investigated one functional polymorphism of the COMT gene and two polymorphisms of the NET gene. EF were assessed by means of the Trail Making Test (TMT) and the Wisconsin Card Sorting Test (WCST). We assessed the effect of each of the three genotypes on EF for the whole sample (N = 318) and separately in schizophrenic (N = 66), bipolar (N = 94) and healthy subjects (i.e., relatives and controls N = 158). Separate analyses were performed because of the presence, in patients samples, of potentially confounding factors, especially medication. Genotype had no significant effect on the cognitive measures in any of the analyses (for the two EF measures, the three polymorphisms, and the four groups). In our sample we found no evidence in favor of a major effect of COMT or NET polymorphisms on the two tests of EF. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741933      PMCID: PMC2755767          DOI: 10.1002/ajmg.b.30352

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  34 in total

1.  Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis.

Authors:  Andrei Szöke; Franck Schürhoff; Flavie Mathieu; Alexandre Meary; Serban Ionescu; Marion Leboyer
Journal:  Psychol Med       Date:  2005-06       Impact factor: 7.723

2.  Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow.

Authors:  B-C Ho; T H Wassink; D S O'Leary; V C Sheffield; N C Andreasen
Journal:  Mol Psychiatry       Date:  2005-03       Impact factor: 15.992

3.  Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of the French version.

Authors:  M Preisig; B T Fenton; M L Matthey; A Berney; F Ferrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

Review 4.  Psychiatric genetics: search for phenotypes.

Authors:  M Leboyer; F Bellivier; M Nosten-Bertrand; R Jouvent; D Pauls; J Mallet
Journal:  Trends Neurosci       Date:  1998-03       Impact factor: 13.837

5.  Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders.

Authors:  G Stöber; M M Nöthen; P Pörzgen; M Brüss; H Bönisch; M Knapp; H Beckmann; P Propping
Journal:  Am J Med Genet       Date:  1996-11-22

6.  Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment.

Authors:  Silvana Galderisi; Mario Maj; Brian Kirkpatrick; Paola Piccardi; Armida Mucci; Giordano Invernizzi; Alessandro Rossi; Stefano Pini; Antonio Vita; Paolo Cassano; Paolo Stratta; Giovanni Severino; Maria Del Zompo
Journal:  Neuropsychobiology       Date:  2005-07-19       Impact factor: 2.328

7.  Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.

Authors:  T Lotta; J Vidgren; C Tilgmann; I Ulmanen; K Melén; I Julkunen; J Taskinen
Journal:  Biochemistry       Date:  1995-04-04       Impact factor: 3.162

8.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

9.  The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale.

Authors:  P Bech; T G Bolwig; P Kramp; O J Rafaelsen
Journal:  Acta Psychiatr Scand       Date:  1979-04       Impact factor: 6.392

10.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

Authors:  R W Heinrichs; K K Zakzanis
Journal:  Neuropsychology       Date:  1998-07       Impact factor: 3.295

View more
  10 in total

Review 1.  COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation.

Authors:  Elisa Ira; Martina Zanoni; Mirella Ruggeri; Paola Dazzan; Sarah Tosato
Journal:  J Psychiatry Neurosci       Date:  2013-11       Impact factor: 6.186

Review 2.  Cognitive control deficits in schizophrenia: mechanisms and meaning.

Authors:  Tyler A Lesh; Tara A Niendam; Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

Review 3.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  The endophenotype concept in psychiatric genetics.

Authors:  Jonathan Flint; Marcus R Munafò
Journal:  Psychol Med       Date:  2006-09-18       Impact factor: 7.723

Review 5.  Neurocognitive functioning in euthymic patients with bipolar disorder and unaffected relatives: A review of the literature.

Authors:  Stephanie A Cardenas; Layla Kassem; Melissa A Brotman; Ellen Leibenluft; Francis J McMahon
Journal:  Neurosci Biobehav Rev       Date:  2016-08-05       Impact factor: 8.989

Review 6.  The Role of a Catechol-O-Methyltransferase (COMT) Val158Met Genetic Polymorphism in Schizophrenia: A Systematic Review and Updated Meta-analysis on 32,816 Subjects.

Authors:  Thelma Beatriz González-Castro; Yazmin Hernández-Díaz; Isela Esther Juárez-Rojop; María Lilia López-Narváez; Carlos Alfonso Tovilla-Zárate; Ana Fresan
Journal:  Neuromolecular Med       Date:  2016-03-28       Impact factor: 3.843

7.  COMT and STH polymorphisms interaction on cognition in schizophrenia.

Authors:  Marta Bosia; Alessandro Pigoni; Adele Pirovano; Cristina Lorenzi; Marco Spangaro; Mariachiara Buonocore; Margherita Bechi; Federica Cocchi; Carmelo Guglielmino; Placido Bramanti; Enrico Smeraldi; Roberto Cavallaro
Journal:  Neurol Sci       Date:  2014-10-05       Impact factor: 3.307

Review 8.  Cognitive heterogeneity in schizophrenia.

Authors:  Eileen M Joyce; Jonathan P Roiser
Journal:  Curr Opin Psychiatry       Date:  2007-05       Impact factor: 4.741

9.  Differential effects of the catechol-O-methyltransferase Val158Met genotype on the cognitive function of schizophrenia patients and healthy Japanese individuals.

Authors:  Shoko Tsuchimine; Norio Yasui-Furukori; Ayako Kaneda; Sunao Kaneko
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

10.  Differences in executive function among patients with schizophrenia, their unaffected first-degree relatives and healthy participants.

Authors:  Yuzuru Kataoka; Takamitsu Shimada; Yoko Koide; Hiroaki Okubo; Takashi Uehara; Toshiki Shioiri; Yasuhiro Kawasaki; Kazutaka Ohi
Journal:  Int J Neuropsychopharmacol       Date:  2020-07-21       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.